Armistice Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Armistice Capital’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,292,000	Closed	-$3.84M	–	65
2016 Q3	$3.84M	Buy	1,292,000 +492,000	+62%	+$853K	1.23%	32
2016 Q2	$1.19M	Sell	800,000 -698,000	-47%	-$1.6M	0.45%	43
2016 Q1	$5.54M	Buy	1,498,000 +296,000	+25%	+$1.83M	2.18%	18
2015 Q4	$12.1M	Buy	+1,202,000	New	+$14.5M	4.33%	8
2015 Q1	–	Sell	-372,000	Closed	-$7.79M	–	36
2014 Q4	$7.79M	Buy	+372,000	New	+$9.37M	3.74%	14

Armistice Capital's AEGR Position: Q4 2016 in Review

Armistice Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 1,292,000 shares — an estimated $3.84M sold.

Armistice Capital first reported a position in AEGR in Q4 2014 and held it in 5 quarters. The position peaked at $12.1M in Q4 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Armistice Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Armistice Capital sold 1,292,000 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $3.84M.
Armistice Capital first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Armistice Capital's Aegerion Pharmaceuticals position peaked at $12.1M in Q4 2015.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Armistice Capital's 13F filing for Q4 2016, filed 15 Feb 2017.